Filing Details
- Accession Number:
- 0001144204-14-042684
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-07-11 22:00:21
- Reporting Period:
- 2014-07-10
- Filing Date:
- 2014-07-11
- Accepted Time:
- 2014-07-11 21:00:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1283972 | Dr R Klaus Veitinger | C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-07-10 | 391 | $21.50 | 2,171 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-07-10 | 233 | $216.88 | 1,938 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-07-10 | 158 | $222.50 | 1,780 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Option to Purchase Common Stock | Disposition | 2014-07-10 | 391 | $0.00 | 391 | $21.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
12,589 | 2022-11-16 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 13, 2014.
- On November 16, 2012, the reporting person was granted 12,980 options to purchase common stock, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares of common stock underlying this option (541 shares) will vest on August 9, 2014, subject to the terms and conditions of the award and the 2012 Plan.